ArticleBMC infectious diseases2025
The prevalence trends of Trichomonas vaginalis infection among women in Jingzhou, central of China, 2019-2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTrichomonas vaginalis (T. vaginalis) is one of the most prevalent sexually transmitted infections globally, with significant regional variations in its prevalence. This study aimed to examine the epidemiological characteristics of T. vaginalis infection in Jingzhou, Hubei Province, China.
methodsTo obtain the prevalence of T. vaginalis infection among age groups and different years, a total of 115,775 patients from 2019 to 2023 were included in this study. Two detection methods including immunochromatographic assay and wet mount microscopy were used to detect the pathogens in vaginal swabs samples including T. vaginalis with other vaginal pathogens, such as Candida albicans (C. albicans) and Gardnerella Vaginalis (G. vaginalis).
resultsThe overall prevalence of T. vaginalis in Jingzhou was 3.41%, demonstrating a decreasing trend from 2019 to 2023, with a particularly significant decrease during the COVID-19 pandemic in 2020-2022 (P < 0.001). The highest positive rate of T. vaginalis was observed in the 45-54 years age group (4.87%), while the lowest rate was observed in the 25-34 years age group (2.37%). The prevalence of T. vaginalis in pregnant women (0.83%) was lower than that in non-pregnant women (1.87%), with a statistically significant difference (P < 0.001). T. vaginalis had co-infection with other pathogens (2.76%) compared to single infection (0.65%), and the most common co-infection pattern was T. vaginalis and G. vaginalis (2.09%). The results showed that there was relative high consistency (Kappa: 0.841) between the immunochromatographic assay and wet mount microscopy method for the detection of T. vaginalis. Additionally, elevated leukocyte levels were associated with a higher prevalence of T. vaginalis.
conclusionThe overall infection rate of T. vaginalis was 3.41%, showing a decreasing trend in prevalence in Jingzhou from 2019 to 2023. The prevalence was the highest in the 45-54 years age group. The study suggested that the immunochromatographic assay should be widely implemented as a screening method for T. vaginalis in primary healthcare facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.